Comparing the current results to its competitors, Dermtech Inc reported Revenue increase in the 1 quarter 2024 by 6.79 % year on year, while most of its competitors have experienced contraction in revenues by -3.66 %, achieved in the same quarter.
Dermtech Inc 's Comment on Competition and Industry Peers
The molecular diagnostics market includes various manufacturers and distributors of molecular diagnostic tests, as well as medical devices and technologies used to assist physicians in evaluating pigmented lesions and diagnosing skin cancer. The company is currently the only provider of a non-invasive genomics test for clinical dermatology professionals. Competitors in the field include LEO Pharma A/S, a Danish pharmaceutical company, and Mindera Corporation, an early-stage start-up, both developing minimally invasive genomic tests for skin disease assessment. Castle Biosciences, Inc. has introduced gene expression assays as CLIA tests.
With revenue growth of 6.79 % within Overall company, Dermtech Inc achieved improvement in market share, within Overall company to approximately 0.05 %. << More on DMTK Market Share.
*Market share is calculated based on total revenue.
January 31, 2024
DermTech, a pioneering company in precision dermatology leveraging non-invasive skin genomics technology, has recently revealed its plans to implement additional restructuring measures. The is to prioritize revenue growth, streamline operations, and further reduce overall operating expenses. DermTech has diligently assessed its growth opportunities and operations, directing a significant portion of its resources towards expanding its reimbursed DermTech Melanoma test. analysis:In recent news, DermTech Inc. announced its decision to embark on additional restructuring actions aimed at fueling revenue growth while enhancing operational efficiency. These measures come as part of the company s concerted effort t...
January 18, 2024
DermTech, Inc. (NASDAQ: DMTK), a leading provider of precision dermatology solutions powered by non-invasive skin genomics technology, recently announced positive topline results from two studies evaluating the DermTech Melanoma Test (DMT). These studies demonstrate the test s ability to accurately diagnose and rule out melanoma across all skin types in real-world clinical settings. The groundbreaking findings further establish the DMT as a valuable tool in precision dermatology.Evaluation of Foundational Gene Expression AssayThe first study, which evaluated the foundational gene expression assay of the DMT, showcased its high negative predictive value. This non-invasive gene expression analysis successfully...
Caredx Inc is a precision medicine company with a business model focused on transplant diagnostics. They develop and commercialize non-invasive tests to identify and monitor organ transplant rejection. By offering innovative solutions and services in the transplant field, Caredx Inc aims to improve outcomes for patients and provide healthcare professionals with valuable information to guide treatment decisions.
Fulgent Genetics Inc is a genetic testing company that offers comprehensive, flexible, and affordable genetic testing solutions for various applications, including clinical diagnostics, carrier screening, and genetic research.
Guardant Health Inc's business model revolves around providing advanced genomic testing services for cancer patients. It specializes in developing liquid biopsy tests that analyze circulating tumor DNA (ctDNA) in the blood. These tests help in early cancer detection, treatment selection, and monitoring of cancer progression. Guardant Health Inc collaborates with healthcare providers, pharmaceutical companies, and researchers to provide these innovative tests and contribute to the advancement of precision medicine in oncology.
MDxHealth SA is a biotech company that primarily focuses on developing and commercializing molecular diagnostic tests to assist healthcare professionals in making informed treatment decisions for cancer patients. Their business model revolves around providing accurate and actionable diagnostic information to improve patient outcomes and potentially reduce healthcare costs.
Sources:
Dermtech Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Dermtech Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
